Drug Trial Radar · NCT07621718
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
670
Planned (sponsor's estimate)
Start
May 22, 2026
Primary completion
Dec 30, 2028
Study completion Apr 22, 2030
Sponsor
- Lead sponsor
- Revolution Medicines, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.
Conditions
- Pancreatic Cancer
- Pancreatic Cancer Metastatic
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Pancreatic Adenocarcinoma Metastatic
- Pancreatic Adenocarcinoma
- Pancreatic Adenosquamous Carcinoma
Interventions
ZoldonrasibDrug
oral tablets
PlaceboDrug
oral tablets
OxaliplatinDrug
IV infusion
Leucovorin (Calcium Folinate)Drug
IV infusion
5-FluorouracilDrug
IV infusion
IrinotecanDrug
IV infusion
Gemcitabine (GEM)Drug
IV infusion
Nab-paclitaxelDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS)Time frame: Up to approximately 4 years
- Overall survival (OS)Time frame: Up to approximately 4 years
Locations
25 sites in 5 countries. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Phoenix, Arizona · Recruiting
The University of Arizona Cancer Center-North Campus
Tucson, Arizona · Recruiting
Yale University
New Haven, Connecticut · Recruiting
University of Florida
Gainesville, Florida · Recruiting
Mayo Clinic Florida
Jacksonville, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Piedmont Cancer Institute
Atlanta, Georgia · Recruiting
Piedmont Healthcare
Atlanta, Georgia · Recruiting
University of Chicago Medical Center
Chicago, Illinois · Recruiting
Johns Hopkins University
Baltimore, Maryland · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Mayo Clinic Rochester
Rochester, Minnesota · Recruiting
Astera Cancer Care
East Brunswick, New Jersey · Recruiting
Rutgers Cancer University
New Brunswick, New Jersey · Recruiting
Columbia University Irving Medical Center
New York, New York · Recruiting
Duke Cancer Center
Durham, North Carolina · Recruiting
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee · Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Universitatsklinikum der PMU Salzburg Landeskrankenhaus
Salzburg, Austria · Recruiting
Azienda Ospedaliera Universitaria Careggi
Florence, Italy · Recruiting
Instituto Oncologico Veneto - IRCCS
Padova, Italy · Recruiting
Radboud UMC
Nijmegen, Netherlands · Recruiting
St Bartholomew's Hospital - Barts Health NHS Trust
London, United Kingdom · Recruiting
Royal Marsden Hospital
London, United Kingdom · Recruiting
Imperial College Healthcare NHS Foundation Trust - Hammersmith Hospital
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.